TAKEDA PHARMACEUTICAL CO LTD current report, Q3 FY2022

Full document

Takeda Pharmaceutical Co Ltd - Q1 2023 (Ended June 30, 2022) Summary

Business Context and Reporting Period

This Form 6-K reports Takeda Pharmaceutical Company Limited's Quarterly Securities Report for the first quarter of its 146th Business Term, covering the period from April 1, 2022, to June 30, 2022. The report was filed with the Kanto Local Finance Bureau in Japan on August 4, 2022. Takeda operates as a global biopharmaceutical company with core therapeutic areas in Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT) Immunology, Oncology, and Neuroscience.

Key Financial Metrics

Metric (JPY Millions) Q1 2022 Q1 2021
Revenue 972,465 949,603
Operating Profit 150,515 248,552
Profit Before Tax 155,473 222,978
Net Profit 105,021 137,726
Net Cash from Operating Activities 84,241 166,858
Cash and Cash Equivalents (End of Period) 645,991 654,920
Total Assets 14,065,426 12,657,234
Total Equity 6,317,383 5,238,643
Bonds and Loans (Total) 4,602,254 4,345,411

Note: All figures are in JPY millions unless otherwise stated. Q1 2021 figures are restated for comparability where applicable.

Material Changes vs. Prior Period

  • Revenue Growth: Revenue increased by 2.4% (22.9 billion JPY) to 972.5 billion JPY. On a Constant Exchange Rate (CER) basis, revenue decreased by 6.8%. The reported increase was driven by favorable foreign exchange rates and business momentum, partially offset by the absence of a one-time 133.0 billion JPY revenue recognition from the sale of a diabetes portfolio in Japan recorded in Q1 2021.
  • Profit Decline: Operating profit fell 39.4% to 150.5 billion JPY, and Net Profit decreased 23.7% to 105.0 billion JPY. The decline in operating profit was primarily due to increased amortization and impairment losses (up 27.7%), higher R&D expenses (up 17.2%), and the absence of the prior year's non-recurring revenue.
  • Core Performance: Excluding non-recurring items, Core Operating Profit increased 28.2% to 319.1 billion JPY, and Core EPS rose 28.5% to 145 JPY, indicating underlying operational strength despite reported GAAP declines.
  • Product Performance:
    • GI: Revenue up 28.4%, led by ENTYVIO (+34.2%).
    • Rare Diseases: Revenue up 16.8%, driven by TAKHZYRO (+33.7%) and REPLAGAL (+25.3%).
    • PDT Immunology: Revenue up 32.3%, with strong growth in immunoglobulin products.
    • Oncology: Revenue down 3.2% due to rapid generic erosion of VELCADE (-45.3%) in the U.S.
  • Geographic Mix: Japan revenue dropped 45.7% due to the prior year's diabetes portfolio sale. U.S. revenue grew 21.6%, and Europe/Canada grew 15.0%.

Outlook, Risks, and Management Commentary

  • Management Commentary: Management highlighted strong growth in core therapeutic areas and "Growth and Launch Products," which increased 40.3% year-over-year. The company continues to focus on R&D in Innovative Biopharma, PDT, and Vaccines.
  • Risks and Contingencies:
    • Geopolitical: Takeda has suspended non-essential activities in Russia (new investments, advertising, clinical trials) while maintaining supply to patients. Revenue from Russia/CIS represented 1.8% of total revenue. No material financial impact was recorded in the current period, but future results could be adversely affected.
    • COVID-19: The company continues to monitor the pandemic's impact. Takeda is manufacturing NUVAXOVID in Japan and distributing SPIKEVAX in partnership with Moderna.
    • Patent Expirations: Continued generic erosion of key products like VELCADE remains a significant headwind in the Oncology segment.
  • Unusual Items: The prior year included a 62.7 billion JPY tax charge related to the Shire/AbbVie break fee, which lowered the effective tax rate comparison. The current period included a gain on prior equity method investments related to the acquisition of GammaDelta Therapeutics and Adaptate Biotherapeutics.

Key Facts for Investor Verification

  • Core vs. GAAP Divergence: Verify the sustainability of the 28.2% growth in Core Operating Profit versus the 39.4% decline in GAAP Operating Profit, driven largely by amortization and the one-time prior-year revenue.
  • Oncology Headwinds: Assess the long-term impact of VELCADE's generic erosion on the Oncology segment's future revenue trajectory.
  • Japan Revenue Normalization: Confirm that the 45.7% drop in Japan revenue is fully attributable to the one-time diabetes portfolio sale and does not indicate broader market weakness.
  • Cash Flow Trends: Monitor the 50% decrease in Net Cash from Operating Activities (from 166.9B to 84.2B JPY) to ensure it is not a recurring trend.
  • Russia Exposure: Track the 1.8% revenue exposure to Russia/CIS and the potential for further operational disruptions or sanctions impacts.